March 29, 2011
VBL Therapeutics to Present at 10th Annual Needham Healthcare Conference

FOR IMMEDIATE RELEASE

 

Media Contact:

 

Dan Budwick, Pure Communications

dan@purecommunicationsinc.com

973-271-6085

 

VBL Therapeutics to Present at 10th Annual Needham Healthcare Conference

 

TEL AVIV, Israel, March 29, 2011 – VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer, will present at the 10th Annual Needham Healthcare Conference. Dr. Harats’ presentation is scheduled to begin at 10:00 a.m. EDT on Tuesday, April 5, 2011 at the New York Palace Hotel in New York City.

 

Dr. Harats is expected to discuss VBL’s business strategy and to provide updates on the clinical progress of the company’s innovative pipeline of first-in-class treatments for immune-inflammatory diseases and cancer.

 

About VBL Therapeutics

 

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company’s lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visitwww.vblrx.com.